Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22444908 | 1.00 | OPRM1 (0.38) | OPRM1OPRK1OPRL1CYP1A2HTR2A | |
| SCHEMBL22444801 | 1.00 | OPRM1 (0.38) | OPRM1OPRK1OPRL1CYP1A2HTR2A | |
| SCHEMBL18726600 | 0.74 | HDAC4 (0.35) | OPRM1OPRK1OPRL1 | |
| SCHEMBL20005671 | 0.74 | HDAC4 (0.35) | OPRM1OPRK1OPRL1 | |
| SCHEMBL6544207 | 0.72 | OPRM1 (0.44) | OPRM1OPRK1OPRL1HTR2AMMP2 | |
| SCHEMBL18086732 | 0.69 | MEN1 (0.33) | OPRM1OPRK1OPRL1CYP1A2MMP2 | |
| SCHEMBL1071202 | 0.69 | HTR2A (0.41) | OPRM1OPRK1OPRL1HTR2AMMP2 | |
| SCHEMBL1148182 | 0.69 | MMP2 (0.41) | OPRM1OPRK1OPRL1CYP1A2MMP2 | |
| SCHEMBL9407936 | 0.68 | OPRM1 (0.41) | OPRM1OPRK1OPRL1HTR2AMMP2 | |
| SCHEMBL28144933 | 0.68 | OPRM1 (0.33) | OPRM1OPRK1OPRL1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-20 | — | — | US | disclosed |
| EP-4631507-A2 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | Voronoi Inc. (KR) | 2025-10-15 | — | — | EP | disclosed |
| EP-3943491-B1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | VORONOI INC (KR) | 2025-06-18 | — | — | EP | disclosed |
| US-20250019373-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | VORONOI INC. (KR) | 2025-01-16 | — | — | US | disclosed |
| US-12157730-B2 | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | VORONOI INC. (KR) | 2024-12-03 | — | — | US | disclosed |
| US-12152021-B2 | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | VORONOI INC. (KR) | 2024-11-26 | — | — | US | disclosed |
| US-20240317730-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-09-26 | — | — | US | disclosed |
| EP-4421077-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | Voronoi Inc. (KR) | 2024-08-28 | — | — | EP | disclosed |
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| CN-115838369-A | Heteroaryl derivatives, process for preparing the same, and pharmaceutical composition containing the same as active ingredient | 株式会社沃若诺伊 | 2023-03-24 | — | — | CN | disclosed |
| CN-115667251-A | Heteroaryl derivative compound and use thereof | 株式会社沃若诺伊生物 | 2023-01-31 | — | — | CN | disclosed |
| CN-113993866-B | Heteroaryl derivatives, process for preparing the same, and pharmaceutical composition containing the same as active ingredient | 株式会社沃若诺伊 | 2022-10-28 | — | — | CN | disclosed |
| US-11466000-B2 | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | VORONOI INC. (KR) | 2022-10-11 | — | — | US | disclosed |
| US-20220289733-A1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | VORONOI INC. (KR) | 2022-09-15 | — | — | US | disclosed |
| CN-114605400-A | Heteroaryl derivatives, process for preparing the same, and pharmaceutical composition containing the same as active ingredient | 株式会社沃若诺伊 | 2022-06-10 | — | — | CN | disclosed |
| US-20220162203-A1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | VORONOI INC. (KR) | 2022-05-26 | — | — | US | disclosed |
| CN-113993866-A | Heteroaryl derivatives, process for preparing the same, and pharmaceutical composition containing the same as active ingredient | 株式会社沃若诺伊 | 2022-01-28 | — | — | CN | disclosed |
| EP-3943491-A1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | Voronoi Inc. (KR) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020190119-A1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | 주식회사 보로노이 | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157730-B2 | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | ERBB4, ERBB2, EGFR | OPRM1 1418/4885OPRK1 2465/4885OPRL1 1767/4885 |
| US-20220289733-A1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | ERBB4, ERBB2, EGFR | OPRM1 1418/4885OPRK1 2465/4885OPRL1 1767/4885 |
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | OPRM1 3144/4885OPRK1 2935/4885OPRL1 3540/4885 |
| US-20220162203-A1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | ERBB4, ERBB2, EGFR | OPRM1 1418/4885OPRK1 2465/4885OPRL1 1767/4885 |
| US-11466000-B2 | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | ERBB4, ERBB2, EGFR | OPRM1 1418/4885OPRK1 2465/4885OPRL1 1767/4885 |
| US-12152021-B2 | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | ERBB4, ERBB2, EGFR | OPRM1 1418/4885OPRK1 2465/4885OPRL1 1767/4885 |
| US-20240317730-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | OPRM1 3144/4885OPRK1 2935/4885OPRL1 3540/4885 |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | OPRM1 372/4885OPRK1 468/4885OPRL1 153/4885 |
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | OPRM1 129/4885OPRK1 480/4885OPRL1 201/4885 |
| US-20250019373-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | RIPK1, RIPK2, RIPK3 | OPRM1 3959/4885OPRK1 1328/4885OPRL1 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.